SCM
Sarissa Capital Management’s BioCryst Pharmaceuticals BCRX Stock Holding History
| Quarter | Market Value | Status | Shares |
Shares Change % | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q3 | – | Sell |
-1,094,168
| Closed | -$6.76M | – | 11 |
|
|
2024
Q2 | $6.76M | Hold |
1,094,168
| – | – | 1.14% | 8 |
|
|
2024
Q1 | $5.56M | Buy |
1,094,168
+94,168
| +9% | +$478K | 0.97% | 8 |
|
|
2023
Q4 | $5.99M | Buy |
1,000,000
+225,000
| +29% | +$1.35M | 0.92% | 7 |
|
|
2023
Q3 | $5.49M | Hold |
775,000
| – | – | 0.74% | 8 |
|
|
2023
Q2 | $5.46M | Hold |
775,000
| – | – | 0.54% | 9 |
|
|
2023
Q1 | $6.46M | Sell |
775,000
-205,288
| -21% | -$1.71M | 0.83% | 8 |
|
|
2022
Q4 | $11.3M | Sell |
980,288
-410,502
| -30% | -$4.71M | 1.34% | 7 |
|
|
2022
Q3 | $17.5M | Hold |
1,390,790
| – | – | 1.98% | 8 |
|
|
2022
Q2 | $14.7M | Hold |
1,390,790
| – | – | 1.48% | 8 |
|
|
2022
Q1 | $22.6M | Sell |
1,390,790
-2,648,810
| -66% | -$43.1M | 2.14% | 7 |
|
|
2021
Q4 | $55.9M | Buy |
4,039,600
+112,900
| +3% | +$1.56M | 4.84% | 7 |
|
|
2021
Q3 | $56.4M | Sell |
3,926,700
-334,300
| -8% | -$4.8M | 4.43% | 6 |
|
|
2021
Q2 | $67.4M | Sell |
4,261,000
-3,376,700
| -44% | -$53.4M | 5.36% | 7 |
|
|
2021
Q1 | $77.7M | Sell |
7,637,700
-537,300
| -7% | -$5.46M | 7.45% | 6 |
|
|
2020
Q4 | $60.9M | Buy |
8,175,000
+3,314,000
| +68% | +$24.7M | 6.22% | 8 |
|
|
2020
Q3 | $16.7M | Buy |
4,861,000
+3,786,000
| +352% | +$13M | 1.97% | 9 |
|
|
2020
Q2 | $5.12M | Buy |
+1,075,000
| New | +$5.12M | 0.57% | 10 |
|